![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Vertex Pharmaceuticals’ Kidney Disease Drug Does Well in Mid-Stage Study
Vertex Pharmaceuticals’ Kidney Disease Drug Does Well in Mid-Stage Study
Vertex Pharmaceuticals’ investigational kidney disease treatment, VX-147, showed promise in a phase 2 study by lowering damaging urine protein levels by nearly 50 percent.
The mid-stage trial included just 13 participants suffering from focal segmental glomerulosclerosis, a condition caused by inherited variants of the APOL1 gene that makes them at high risk of kidney failure.
Based on the promising results, the company plans to launch a pivotal trial in early 2022.
Upcoming Events
-
21Oct